Drugs / TN-401
TN-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06228924 | Mar 2024 → May 2026 overdue | arrhythmogenic right ventricular cardiomyopathy | Tenaya Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TN-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06228924 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene.” NCT06228924 ↗ |
| Target | PKP2 | “TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene.” NCT06228924 ↗ |